Verteporfin Therapy and Intravitreal Bevacizumab Combined and Alone in Choroidal Neovascularization due to Age-Related Macular Degeneration
Authors:
- Ratimir LazicRLRatimir Lazic
- Nikica GabricNGNikica Gabric
- 1 June 2007
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 114 (6) , 1179-1185
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Intravitreal Avastin: The Low Cost Alternative to Lucentis?American Journal of Ophthalmology, 2006
- SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Verteporfin Therapy Combined with Intravitreal Triamcinolone in All Types of Choroidal Neovascularization due to Age-Related Macular DegenerationOphthalmology, 2006
- NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2005
- GUIDELINES FOR USING VERTEPORFIN (VISUDYNE) IN PHOTODYNAMIC THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION AND OTHER CAUSES: UPDATERetina, 2005
- Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2American Journal of Ophthalmology, 2001
- Exudative macular degeneration and intravitreal triamcinolone A pilot studyAustralian and New Zealand Journal of Ophthalmology, 1995